dm+d

Unassigned

New Medicines

Prevention of recurrence in cancer associated-venous thromboembolism

Information

New molecular entity
Anthos Therapeutics
Anthos Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Fully human, highly selective factor XI monoclonal antibody demonstrating dual inhibitory activity against both Factor XI and its activated form, Factor XIa. Abelacimab can be administered intravenously (IV) to achieve rapid inhibition of Factor XI activity and then used subcutaneously (SC) monthly to maintain nearly complete inhibition in a chronic setting [1,2,3]
The incidence of VTE is 1-2 per 1,000 of the general population, and up to 20% of cancer patients develop blood clots [4,5]
Prevention of recurrence in cancer associated-venous thromboembolism
Intravenous and
Subcutaneous